Please use this identifier to cite or link to this item:
http://adhlui.com.ui.edu.ng/jspui/handle/123456789/2790
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Iwalokun, BA | - |
dc.contributor.author | Hodonu, SO | - |
dc.contributor.author | Olaleye, BM | - |
dc.contributor.author | Olabisi, OA | - |
dc.date.accessioned | 2024-08-26T13:37:12Z | - |
dc.date.available | 2024-08-26T13:37:12Z | - |
dc.date.issued | 2006-09 | - |
dc.identifier.citation | Afr. J. Med. med. Sci. (2006) 35, 337-343 | en_US |
dc.identifier.issn | 1116-4077 | - |
dc.identifier.uri | http://adhlui.com.ui.edu.ng/jspui/handle/123456789/2790 | - |
dc.description | Article | en_US |
dc.description.abstract | Studies have confirmed HBsAg antigenemia as an important correlate ol HIV-1 infections in Nigeria. However, the hepatic pathophysiology and therapeutic implications in antiretroviral regimens are poorly understood. In this study, fifty-four HIV-1 seropositive patients aged 16-4 7 years (mean age 31.8 years) with CD4 T lymphocyte counts of 148 - 420 cells/mm' attending clinics in General Hospital. Ikeja and private medical centres in Lagos Island, Ni geria and forty sex and age-matched apparently healthy controls were serologically examined as carriers of hepati tis B surface antigen (HBsAg) using a particle agglutina tion assay procedure (Sensitivity 94.5 - 100%,Serodia®HBs.PA. Fujirebio. Inc.). HBsAgwas detected in 28 (51.9%) and 5 (12.5%) of the patients and controls respectively (- 2 Mantel-I laenszel = 13.8; P = 0.02). HBV co-infection was found to result in significant (P < 0.05) reduction in total lymphocyte count (1368.6 + 53.2 vs. 1590.5 + 80.4 cells/ mm') with 7 of 10 (70%), 18 of33 (54.5%) and 3 o f 6 (50%) 11IV-1 patients having < 200, 200 - 350 and > 350 CD4 lymphocyte cells/fil and eliciting HBsAg antigenemia. These patients exhibited 2.9 - 8.6% reduction in CD4 T lymphocyte counts compared to their seronegative coun terparts. Although the liver function parameters measured in HIV-1 patients tested were higher than control values, significantly (P < 0.05) elevated liver enzymes: sGOT(44.1 ±2.2 vs. 26.2+ 2.1 !U/L),sGPT (46.2+ 2.4 vs. 23.5 + 1.8 IIJ/ L), and serum bilirubin levels (2.04 + 0.18 vs. 1.0 + 0.07 mg/ dL) were observed in 11 BsAg positive HIV-1 patients. sGOT or sGPT activity that was five times greater than the con trol was observed in 7(25%) and 2 (7.7%) of HbsAg positive and negative HIV-1 patients in whom significant association between decreased total lymphocyte count and measured liver parameters was found. We conclude that hepatitis infection deteriorates liver functions and its investigation in HIV-1 infected patients may be of clino-thera peutic importance prior to antiretroviral therapy administration | en_US |
dc.description.sponsorship | COLLEGE OF MEDICINE | en_US |
dc.language.iso | en | en_US |
dc.publisher | COLLEGE OF MEDICINE | en_US |
dc.subject | Hepatitis B surface antigen (HBsAg), | en_US |
dc.subject | , CD4 T lymphocyte count | en_US |
dc.subject | Theraupetic implications | en_US |
dc.subject | HIV1 infection | en_US |
dc.title | Seroprevalence and biochemical features of hepatitis B surface antigenemia in patients with HIV-1 infection in Lagos, Nigeria | en_US |
dc.type | Article | en_US |
Appears in Collections: | African Journal of Medicine and Medical Sciences |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Iwalokun et al _Seroprevalence_2006.pdf | Article | 14.98 MB | Adobe PDF | View/Open |
Items in COMUI (ADHL) are protected by copyright, with all rights reserved, unless otherwise indicated.